{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:55:15Z","timestamp":1781805315727,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40121-026-01366-9","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:00:59Z","timestamp":1779512459000},"page":"1939-1953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort"],"prefix":"10.1007","volume":"15","author":[{"given":"Alberto","family":"Foncillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"De La Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Chivite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Lu\u00eds","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9. M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5506","authenticated-orcid":false,"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"4","key":"1366_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11901-020-00541-x","volume":"19","author":"HN Kim","year":"2020","unstructured":"Kim HN. Chronic Hepatitis B and HIV coinfection: a continuing challenge in the era of antiretroviral therapy. Curr Hepatol Rep. 2020;19(4):345\u201353. https:\/\/doi.org\/10.1007\/s11901-020-00541-x.","journal-title":"Curr Hepatol Rep"},{"key":"1366_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713981","volume":"8","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Lin P, Cheng N. HBV\/HIV coinfection: impact on the development and clinical treatment of liver diseases. Front Med. 2021;8:713981. https:\/\/doi.org\/10.3389\/fmed.2021.713981.","journal-title":"Front Med"},{"issue":"15","key":"1366_CR3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","volume":"31","author":"KP Singh","year":"2017","unstructured":"Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-Hepatitis B Virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31(15):2035\u201352. https:\/\/doi.org\/10.1097\/QAD.0000000000001574.","journal-title":"AIDS"},{"issue":"9349","key":"1366_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/s0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Mu\u00f1oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(02)11913-1.","journal-title":"Lancet"},{"issue":"10","key":"1366_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jvh.12555","volume":"23","author":"R Rajbhandari","year":"2016","unstructured":"Rajbhandari R, Jun T, Khalili H, Chung RT, Ananthakrishnan AN. HBV\/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. J Viral Hepat. 2016;23(10):820\u20139. https:\/\/doi.org\/10.1111\/jvh.12555.","journal-title":"J Viral Hepat"},{"key":"1366_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745541","volume":"12","author":"Y Tian","year":"2021","unstructured":"Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune response to Hepatitis B Virus vaccine among people living with HIV: a meta-analysis. Front Immunol. 2021;12:745541. https:\/\/doi.org\/10.3389\/fimmu.2021.745541.","journal-title":"Front Immunol"},{"issue":"7","key":"1366_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.vaccine.2012.12.047","volume":"31","author":"VB Lopes","year":"2013","unstructured":"Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful Hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040\u20134. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.047.","journal-title":"Vaccine"},{"issue":"3","key":"1366_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/jvh.13217","volume":"27","author":"L Platt","year":"2020","unstructured":"Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27(3):294\u2013315. https:\/\/doi.org\/10.1111\/jvh.13217.","journal-title":"J Viral Hepat"},{"issue":"11","key":"1366_CR9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","volume":"71","author":"S Leumi","year":"2020","unstructured":"Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of Hepatitis B infection in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Clin Infect Dis. 2020;71(11):2799\u2013806. https:\/\/doi.org\/10.1093\/cid\/ciz1170.","journal-title":"Clin Infect Dis"},{"issue":"25","key":"1366_CR10","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.25.2000236","volume":"26","author":"L P\u00e9rez-Latorre","year":"2021","unstructured":"P\u00e9rez-Latorre L, Berenguer J, Mic\u00e1n R, Montero M, Cifuentes C, Puig T, et al. HIV\/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018. Euro Surveill. 2021;26(25):2000236. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.25.2000236.","journal-title":"Euro Surveill"},{"issue":"6","key":"1366_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eimc.2011.09.003","volume":"30","author":"FA Di Lello","year":"2012","unstructured":"Di Lello FA, Mac\u00edas J, Cifuentes CC, Vargas J, Palomares JC, Pineda JA. Low prevalence of occult HBV infection among HIV-infected patients in Southern Spain. Enferm Infecc Microbiol Clin. 2012;30(6):312\u20134. https:\/\/doi.org\/10.1016\/j.eimc.2011.09.003.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"12","key":"1366_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/cid\/cit145","volume":"56","author":"H Gatanaga","year":"2013","unstructured":"Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis. 2013;56(12):1812\u20139. https:\/\/doi.org\/10.1093\/cid\/cit145.","journal-title":"Clin Infect Dis"},{"key":"1366_CR13","unstructured":"European AIDS Clinical Society. Guidelines version 13.0. November 2025. Available at: https:\/\/eacs.sanfordguide.com\/en\/eacs-hiv\/art\/eacs-initial-regimens-arv-naive-adults. [Accessed February 10, 2026]"},{"key":"1366_CR14","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. September 2024. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/what-to-start-adult-adolescent-arv.pdf. [Accessed February 10, 2026]"},{"issue":"1","key":"1366_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039. (Epub 2014 Oct 31. Erratum in: Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.).","journal-title":"Gastroenterology"},{"issue":"8","key":"1366_CR16","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3201\/eid3008.240019","volume":"30","author":"E Adachi","year":"2024","unstructured":"Adachi E, Sedohara A, Arizono K, Takahashi K, Otani A, Kanno Y, et al. Hepatitis b virus reactivation after switch to cabotegravir\/rilpivirine in patient with low hepatitis b surface antibody. Emerg Infect Dis. 2024;30(8):1668\u201371. https:\/\/doi.org\/10.3201\/eid3008.240019.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"1366_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa367","volume":"7","author":"C Pintado","year":"2020","unstructured":"Pintado C, Delaugerre C, Molina JM. Acute hepatitis B infection after a switch to long-acting cabotegravir and rilpivirine. Open Forum Infect Dis. 2020;7(9):ofaa367. https:\/\/doi.org\/10.1093\/ofid\/ofaa367.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1366_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/QAI.0000000000003239","volume":"94","author":"S Vasishta","year":"2023","unstructured":"Vasishta S, Dieterich D, Mullen M, Aberg J. Brief report: hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion. J Acquir Immune Defic Syndr. 2023;94(2):160\u20134. https:\/\/doi.org\/10.1097\/QAI.0000000000003239.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"1366_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.106","volume":"9","author":"E Welford","year":"2022","unstructured":"Welford E, Yin J, Hill L, Wooten D. 1583. A case series of low-level HBV viremia after switching to long-acting injectable cabotegravir\/rilpivirine in patients with HIV, hepatitis B core antibody positivity, and hepatitis B surface antigen negativity. Open Forum Infect Dis. 2022;9(Suppl 2):ofac492.106. https:\/\/doi.org\/10.1093\/ofid\/ofac492.106.","journal-title":"Open Forum Infect Dis"},{"key":"1366_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf634","author":"F Olcott","year":"2025","unstructured":"Olcott F, Oddie PD, Barlow MJ, et al. Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: a case series and lessons for practice. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf634.","journal-title":"Clin Infect Dis"},{"key":"1366_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26279","volume":"27","author":"D Fox","year":"2024","unstructured":"Fox D, Slim J, Overton ET, Doblado-Maldonado A, Jeffery P, Grove RA, et al. Efficacy of dolutegravir, lamivudine (DTG, 3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3, 3b GEMINI-1, -2, STAT, TANGO, and SALSA. [IAS Abstract 0106LB] Abstract Supplement Abstracts from AIDS, the 25th International AIDS Conference, 22\u201326 July, Munich, Germany & Virtual. J Int AIDS Soc. 2024;27:e26279. https:\/\/doi.org\/10.1002\/jia2.26279.","journal-title":"J Int AIDS Soc"},{"key":"1366_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag001","author":"RV Denyer","year":"2026","unstructured":"Denyer RV, Tate JP, Benator DA, Lim JK, Weintrob A. Hepatitis B Reactivation in a US Cohort of people with human immunodeficiency virus and hepatitis B core antibody after switch to antiretroviral therapy without Hepatitis B activity. Clin Infect Dis. 2026. https:\/\/doi.org\/10.1093\/cid\/ciag001.","journal-title":"Clin Infect Dis"},{"key":"1366_CR23","unstructured":"Salpini R., D\u2019Anna S., Alkhatib M., Piermatteo L., Tavelli A., Quiros E., Cingolani A., Papalini C., Carrara S., Malagnino V., et al. (2022) Reactivation of hepatitis B virus is a frequent event in anti-HBc positive\/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays; Proceedings of the 14th Congress National\u00e2\u20ac\u201dICAR; Montreal, QC, Canada."},{"issue":"10","key":"1366_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy251","volume":"5","author":"A Abdullahi","year":"2018","unstructured":"Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM. Hepatitis B virus (HBV) infection and re-activation during nucleos(t)ide reverse transcriptase inhibitor-sparing antiretroviral therapy in a high-HBV endemicity setting. Open Forum Infect Dis. 2018;5(10):ofy251. https:\/\/doi.org\/10.1093\/ofid\/ofy251.","journal-title":"Open Forum Infect Dis"},{"key":"1366_CR25","doi-asserted-by":"publisher","first-page":"A73","DOI":"10.1136\/sextrans-ICAR-2024.67","volume":"100","author":"P Salvo","year":"2024","unstructured":"Salvo P, Iannone V, Passerotto R, et al. SC-4 risk of hepatitis B reactivation in people with HIV (PWH) with isolated anti-core antibody (HBcAb) after switch to 2DR strategies with lamivudine (3TC)\/dolutegravir (DTG). Sex Transm Infect. 2024;100:A73\u20134. https:\/\/doi.org\/10.1136\/sextrans-ICAR-2024.67.","journal-title":"Sex Transm Infect"},{"issue":"1","key":"1366_CR26","first-page":"583","volume":"32","author":"G Morsica","year":"2024","unstructured":"Morsica G, Lolatto R, Diotallevi S, et al. Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen. [CROI Abstract 737] In Special Issue: Abstracts From the CROI 2024 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2024;32(1):583.","journal-title":"Top Antivir Med."},{"key":"1366_CR27","doi-asserted-by":"publisher","first-page":"A71","DOI":"10.1136\/sextrans-ICAR-2024.65","volume":"100","author":"V Malagnino","year":"2024","unstructured":"Malagnino V, Giacomelli A, Rossotti R, et al. SC-2 safety and effectiveness of switching PWH with occult HBV infection to tenofovir-sparing regimens. Sex Transm Infect. 2024;100:A71\u20132. https:\/\/doi.org\/10.1136\/sextrans-ICAR-2024.65.","journal-title":"Sex Transm Infect"},{"key":"1366_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107294","volume":"150","author":"R Salpini","year":"2025","unstructured":"Salpini R, D\u2019Anna S, Alkhatib M, et al. Kinetics of hepatitis B virus replication in anti-HBc positive\/HBsAg-negative people with HIV switching to tenofovir sparing therapy. Int J Infect Dis. 2025;150:107294. https:\/\/doi.org\/10.1016\/j.ijid.2024.107294.","journal-title":"Int J Infect Dis"},{"key":"1366_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/hiv.70104","volume":"26","author":"L Begr\u00e9","year":"2025","unstructured":"Begr\u00e9 L, Akotia MK, Boyd A, et al. Low risk of HBV reactivation in HBcAb-positive\/HBsAg-negative persons with HIV switching to non-tenofovir-based antiretroviral therapy EACS Abstract. HIV Med. 2025;26:5\u2013701. https:\/\/doi.org\/10.1111\/hiv.70104.","journal-title":"HIV Med"},{"issue":"1","key":"1366_CR30","first-page":"332","volume":"33","author":"MdM Arcos-Rueda","year":"2025","unstructured":"Arcos-Rueda MdM, de Gea-Grela A, Ramos L, et al. Hepatitis B reactivation PWH with isolated anti-core pattern on therapies excluding tenofovir [CROI Abstract 770]. In Special Issue: Abstracts From the CROI 2025 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2025;33(1):332.","journal-title":"Top Antivir Med"},{"issue":"1","key":"1366_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAD.0000000000004353","volume":"40","author":"DT Dieterich","year":"2026","unstructured":"Dieterich DT, Brunet L, Hsu RK, et al. Monitoring and risk of hepatitis B reactivation and Hepatitis flare during tenofovir interruption among people with HIV and Hepatitis B. AIDS. 2026;40(1):43\u201351. https:\/\/doi.org\/10.1097\/QAD.0000000000004353. (Epub 2025 Sep 22. PMID: 40971446; PMCID: PMC12700698).","journal-title":"AIDS"},{"key":"1366_CR32","unstructured":"Haser G, Lisha N, Kin HN. Hepatitis B reactivation\/infection in people with HIV on tenofovir-sparing antiretroviral therapy. [CROI Abstract 142]. CROI 2026 Conference on Retroviruses and Opportunistic."},{"issue":"1","key":"1366_CR33","first-page":"332","volume":"33","author":"K Ring","year":"2025","unstructured":"Ring K, Orkin C, Parczewski M, et al. HBV reactivation post-switch to HBV-inactive ART: a scoping review. [CROI Abstract 771]. In Special Issue: Abstracts From the CROI 2025 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2025;33(1):332.","journal-title":"Top Antivir Med"},{"key":"1366_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag023","author":"A Foncillas","year":"2026","unstructured":"Foncillas A, Ambrosioni J, Sempere A, et al. Hepatitis B outcomes after switching to long-acting cabotegravir\/rilpivirine in people with HIV: reactivation, incident infection, and liver safety across diverse serological profiles. Clin Infect Dis. 2026. https:\/\/doi.org\/10.1093\/cid\/ciag023.","journal-title":"Clin Infect Dis"},{"key":"1366_CR35","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata statistical software: release 18. College Station, TX: StataCorp LLC; 2023."},{"issue":"4","key":"1366_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ijid.2008.08.018","volume":"13","author":"C Firnhaber","year":"2009","unstructured":"Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009;13(4):488\u201392. https:\/\/doi.org\/10.1016\/j.ijid.2008.08.018.","journal-title":"Int J Infect Dis"},{"issue":"9349","key":"1366_CR37","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/s0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Mu\u00f1oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(02)11913-1.","journal-title":"Lancet"},{"issue":"6","key":"1366_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","volume":"19","author":"D Konopnicki","year":"2005","unstructured":"Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593\u2013601.","journal-title":"AIDS"},{"issue":"3","key":"1366_CR39","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.31839","volume":"74","author":"HN Kim","year":"2021","unstructured":"Kim HN, Newcomb CW, Carbonari DM, Roy JA, et al. Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America. Hepatology. 2021;74(3):1190\u2013202. https:\/\/doi.org\/10.1002\/hep.31839.","journal-title":"Hepatology"},{"key":"1366_CR40","unstructured":"Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO\/CDS\/HIV\/19.15). Licence: CC BY-NC-SA 3.0 IGO. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/0d7426a0-bdb1-4b0f-b2ba-fc5cfb130d58\/content. [Accessed March 19, 2026]."},{"issue":"13","key":"1366_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/s0264-410x(99)00389-8","volume":"18","author":"D Rey","year":"2000","unstructured":"Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000;18(13):1161\u20135. https:\/\/doi.org\/10.1016\/s0264-410x(99)00389-8.","journal-title":"Vaccine"},{"issue":"2","key":"1366_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jmv.1890310207","volume":"31","author":"RH Loke","year":"1990","unstructured":"Loke RH, Murray-Lyon IM, Coleman JC, et al. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J Med Virol. 1990;31(2):109\u201311. https:\/\/doi.org\/10.1002\/jmv.1890310207.","journal-title":"J Med Virol"},{"issue":"4","key":"1366_CR43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/00002030-199404000-00024","volume":"8","author":"SC Tayal","year":"1994","unstructured":"Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS. 1994;8(4):558\u20139. https:\/\/doi.org\/10.1097\/00002030-199404000-00024.","journal-title":"AIDS"},{"issue":"1","key":"1366_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","volume":"67","author":"S Schillie","year":"2018","unstructured":"Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1\u201331. https:\/\/doi.org\/10.15585\/mmwr.rr6701a1.","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"1366_CR45","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.vaccine.2012.12.047","volume":"31","author":"VB Lopes","year":"2013","unstructured":"Lopes VB, Hassing RJ, de Vries-Sluijs TE, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040\u20134. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.047.","journal-title":"Vaccine"},{"issue":"4","key":"1366_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jama.2024.24490","volume":"333","author":"KM Marks","year":"2025","unstructured":"Marks KM, Kang M, Umbleja T, et al. HepB-CpG vs HepB-Alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial. JAMA. 2025;333(4):295\u2013306. https:\/\/doi.org\/10.1001\/jama.2024.24490.","journal-title":"JAMA"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01366-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:33:16Z","timestamp":1781803996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01366-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01366-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alberto Foncillas has received honoraria for lectures and\/or AB from ViiV Healthcare, Gilead Sciences and J&J outside the submitted work. Lorena De La Mora has received honoraria for lectures and\/or AB from ViiV Healthcare, Gilead Sciences and J&J outside the submitted work. J\u00falia Calvo has received honoraria for lectures or AB and traveling support from ViiV Healthcare, Gilead Sciences, and Janssen outside the submitted work. Abiu Sempere has received honoraria for lectures and\/or research grants and traveling support from Gilead Sciences, ViiV Healthcare, and MSD outside the submitted work. Maria Mart\u00ednez-Rebollar has received honoraria for lectures or AB from Gilead Sciences, ViiV Healthcare, and J&J and has received honoraria for leadership role from Gilead Sciences and traveling support from Gilead Sciences outside the submitted work. Berta Torres has received honoraria for lectures, AB and\/or research grants from Gilead Sciences, GSK, MSD, and J&J and traveling support from Gilead Sciences outside the submitted work. Ana Gonz\u00e1lez-Cord\u00f3n has received honoraria for lectures or AB, consulting fees, and\/or research grants from Gilead Sciences, Janssen, Merck Sharp & Dohme, and ViiV Healthcare and traveling support from Gilead Sciences, J&J, ViiV Healthcare, and MSD outside the submitted work. Jose Lu\u00eds Blanco has received honoraria for lectures or AB and\/or research grants and traveling support from Gilead Sciences, ViiV Healthcare, and MSD outside the submitted work. Jos\u00e9. M. Mir\u00f3 has received consulting honoraria and\/or research grants from Angelini, Basilea, Contrafect, Cubist, Genentech, Gilead Sciences, Janssen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare outside the submitted work. Esteban Mart\u00ednez has received honoraria for lectures or AB and\/or research grants from Gilead Sciences, ViiV Healthcare, and MSD outside the submitted work, and has held unpaid leadership roles as past president of EACS and as president of NEAT ID. Montserrat Laguno has received research funding from ViiV Healthcare and Gilead Sciences, has participated in AB for J&J, and has received personal compensation for presentations from ViiV Healthcare, Gilead Sciences, MSD, and J&J and traveling support from Gilead Sciences, outside the submitted work. Juan Ambrosioni has received research funding from ViiV Healthcare and Gilead Sciences, has participated in AB for ViiV, Gilead Sciences, MSD and J&J; has received personal compensation for presentations from ViiV, Gilead Sciences, MSD and J&J; and has participated in DSMB for HIPRA and Grifols. All other authors (Leire Berrocal, Elisa de Lazzari, Ivan Chivite, Alexy Inciarte, and Josep Mallolas) report no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was approved by the Ethics Committee of the Hospital Clinic of Barcelona (protocol no. HCB\/2025\/0752).\u00a0Given the retrospective nature of the study, its potential utility for society, and in accordance with the relevant legislation (Articles 6.1.e and 9.2j of the General Data Protection Regulation [GDPR], as well as Additional Disposition 17.2.d of LOPD-GDD 3\/2018), the Ethics Committee of the Hospital Clinic of Barcelona waived the requirement for written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}